What Causes Sma The Smn1 Gene Explained? The Reason

Spinal muscular atrophy (SMA) happens because of a problem with a specific gene called SMN1. This gene normally makes a protein that your motor neurons need to survive. When the SMN1 gene is missing or broken, those nerve cells die, and muscles stop getting the signals they need to move. The result is progressive muscle weakness that usually begins in the trunk and legs. This is a genetic condition, meaning it is passed down through families, and it is one of the most common genetic causes of death in infants.

What Exactly Does the SMN1 Gene Do?

Every cell in your body contains DNA, which acts as an instruction manual. The SMN1 gene holds the instructions for making something called the survival motor neuron (SMN) protein. Despite its name, this protein is active in every cell, not just nerve cells.

Its main job is helping to process RNA, the molecule that reads DNA instructions and builds proteins. When SMN protein levels are too low, cells throughout the body struggle, but motor neurons in the spinal cord are especially sensitive. These are the large nerve cells that send signals from your spinal cord to your muscles. Without enough SMN protein, these neurons die off over time, which is why SMA affects movement so severely.

Humans have a second, nearly identical gene called SMN2. The critical difference is that SMN2 only produces a small amount of functional protein. Most of what SMN2 makes is a shortened, unstable version that gets broken down quickly. This is why SMN2 cannot fully replace the lost function of SMN1.

What Causes SMA: The SMN1 Gene Explained

The reason SMA occurs is straightforward at the genetic level: a person inherits two broken copies of the SMN1 gene, one from each parent. This is called an autosomal recessive pattern of inheritance.

Parents who each carry one broken copy and one working copy do not have SMA themselves. They are carriers. When two carriers have a child, there is a 25 percent chance that child inherits both broken copies and develops SMA. There is a 50 percent chance the child will be a carrier like the parents, and a 25 percent chance the child inherits two working copies and is completely unaffected.

The most common genetic error is a deletion, meaning a chunk of the SMN1 gene is entirely missing. In about 95 percent of SMA cases, both copies of the gene have this deletion. The remaining cases involve a mix of deletions and small mutations that also disable the gene.

Why Does SMA Severity Vary So Much?

Not everyone with SMA is affected the same way. The variation comes down to the SMN2 gene. People can have anywhere from zero to eight copies of SMN2, and the number of copies directly influences how severe the disease is.

More copies of SMN2 mean more functional SMN protein, which means milder symptoms and later onset. Fewer copies mean less protein and more severe disease. This is not a perfect rule, but it is a strong predictor of where a person falls on the SMA spectrum.

SMA is traditionally divided into four types based on age of onset and highest motor milestone achieved:

• Type 1: Onset before 6 months. Infants never sit independently. This is the most severe form.
• Type 2: Onset between 6 and 18 months. Children can sit but never walk independently.
• Type 3: Onset after 18 months. Children learn to walk but may lose this ability later.
• Type 4: Onset in adulthood. Mild weakness that typically does not affect lifespan.

These categories are useful clinically, but SMA is really a continuous spectrum. The SMN2 copy number helps explain why one child might be affected before birth while a grandparent with the same genetic diagnosis only notices mild leg weakness at age 50.

How Is SMA Diagnosed?

Diagnosis begins with a physical exam and a careful history of symptoms. Doctors look for symmetrical muscle weakness, poor muscle tone, absent reflexes, and a history of developmental delays. But clinical signs alone are not enough to confirm SMA.

The definitive test is a blood draw that looks for the SMN1 gene deletion. This genetic test is highly accurate. It can identify the missing gene in about 95 percent of cases. If the test finds only one missing copy, doctors will look for other mutations in the remaining copy. A diagnosis is confirmed when both copies of SMN1 are found to be broken or absent.

In the past, doctors often used an electromyography test or a muscle biopsy to support the diagnosis. These are rarely needed today because the genetic test is so reliable. However, they may still be used in unusual cases where the genetic testing is inconclusive.

Can SMA Be Treated?

For most of medical history, SMA had no treatment. Care focused on managing symptoms: breathing support, feeding tubes, physical therapy, and preventing scoliosis. That changed dramatically in the last decade.

There are now three approved disease-modifying therapies for SMA. Each works by increasing the amount of functional SMN protein in the body.

• Nusinersen (Spinraza): Given by injection into the spinal fluid. It works by helping the SMN2 gene produce a longer, more functional protein.
• Risdiplam (Evrysdi): An oral medication taken daily. Like nusinersen, it modifies how SMN2 is read.
• Onasemnogene abeparvovec (Zolgensma): A one-time gene therapy given intravenously. It delivers a working copy of the SMN1 gene into cells.

These treatments are most effective when started early, ideally before symptoms appear. Newborn screening for SMA is now standard in many regions because early treatment dramatically improves outcomes. Infants treated before symptom onset often develop motor skills close to what healthy children achieve.

It is important to be clear: these treatments are not cures. They do not restore motor neurons that have already died. But they can stop or slow further damage, and for many patients, they meaningfully change the course of the disease.

Who Should Get Genetic Testing?

Anyone with a family history of SMA should consider carrier testing before starting a family. This is a simple blood test that tells you whether you carry one broken copy of the SMN1 gene.

Carrier testing is also offered as part of routine prenatal screening in some practices. The American College of Medical Genetics and Genomics recommends offering carrier screening for SMA to all couples, regardless of family history. This is because SMA is common enough that everyone has some risk, and most affected children are born to parents with no family history of the disease.

If both partners are carriers, they have options. These include prenatal testing, preimplantation genetic diagnosis during IVF, and the option to meet with a genetic counselor to discuss what the results mean for their family.

Testing a newborn is different. Newborn screening for SMA is now performed in many states and countries. This screening is not optional in those regions; it happens automatically unless a parent opts out. Early diagnosis through newborn screening is the single most important factor in achieving the best possible outcome with current treatments.

What Is the Prognosis Today?

The prognosis for SMA has changed more in the past decade than in the previous century. Before treatments existed, most infants with SMA type 1 died before age 2. Today, many of those same infants are surviving into childhood and beyond, though they still require significant medical support.

For milder forms of SMA, the outlook is generally good. People with type 3 or type 4 often have normal or near-normal lifespans. They may need mobility aids or accommodations over time, but they can live full, independent lives.

Even with treatment, results vary widely. Some children respond remarkably well and achieve motor milestones their doctors never expected. Others respond partially. The variability depends on how much damage existed before treatment began, the number of SMN2 copies, and individual biological factors that researchers are still working to understand.

What Research Is Still Needed?

Current treatments are life-changing, but they are not perfect. They do not cross the blood-brain barrier well, they are expensive, and they require lifelong use in most cases. Researchers are actively working on next-generation therapies that might be more effective or easier to administer.

One major question is whether combination therapy works better than any single treatment. Some clinicians already use more than one approach, but large trials comparing combinations directly are still ongoing. The evidence for combination therapy is promising but not yet definitive.

Another area of study is why motor neurons are so uniquely vulnerable to low SMN protein. Most cells tolerate reduced SMN levels, but motor neurons do not. Understanding this specificity could lead to therapies that protect motor neurons directly, regardless of the underlying genetic cause.